Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0000950170-25-036420 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-03-10 | 2025-03-06 | BBIO | Valantine Hannah | Dir | S - Sale+OE | $32.58 | -12.9K | 1,764 | -88% | -$419.5K |
| DT | 2025-03-10 | 2025-03-06 | BBIO | Valantine Hannah | Dir | M - OptEx | $16.75 | +12.9K | 14.6K | +730% | +$215.7K |
| DT | 2025-03-10 | 2025-03-06 | BBIO | Valantine Hannah | Dir | M - OptEx | $0.00 | -12.9K | 38.6K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-06 | S | D | 12,875 | $32.58 | 1,764 | D | — | — | (F2) Represents the weighted average sale price of the shares sold from $32.17 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-03-06 | M | A | 12,875 | $16.75 | 14,639 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-03-06 | M | D | 12,875 | $0.00 | 38,626 | D | $16.75 · — to 2033-06-21 | 12,875 Common Stock | (F3) The stock option vests in three annual installments starting on June 21, 2024 and ending on June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors. |